Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-007 in Combination With Tislelizumab in the Treatment of Malignancies
NCT05516914Phase 2Completed
- Sponsor
- Leads Biolabs
- Start
- Sep 2022
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alcestobart in malignant neoplasm, sponsored by Leads Biolabs. Primary endpoints: Objective Response Rate, Dose-limiting toxicities and 1 more. Started Sep 2022; status: completed.
02
Drugs
alcestobart
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT05516914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516914.